{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:28:28Z","timestamp":1761647308788},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,11,6]],"date-time":"2004-11-06T00:00:00Z","timestamp":1099699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s00280-004-0871-5","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T15:14:47Z","timestamp":1099667687000},"page":"295-300","source":"Crossref","is-referenced-by-count":39,"title":["A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck"],"prefix":"10.1007","volume":"55","author":[{"given":"Matthew M.","family":"Cooney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou-Yi","family":"Tserng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinit","family":"Makar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Jeff","family":"McPeak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen T.","family":"Ingalls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Ksenich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lavertu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Hoppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Remick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,11,6]]},"reference":[{"key":"CR1","first-page":"804","volume-title":"Cancer: principles and practices of oncology","author":"SP Schantz","year":"2001","unstructured":"Schantz SP, Harrison LB, Forastiere AA (2001) Cancer of the head and neck. In: DeVita VT, Hillman S, Rosenberg SA (eds) Cancer: principles and practices of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia Baltimore, p 804","edition":"6"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00144263","volume":"6","author":"M Al-Sarraf","year":"1987","unstructured":"Al-Sarraf M (1987) Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 6:191","journal-title":"Cancer Metastasis Rev"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0889-8588(18)30408-8","volume":"5","author":"HA Pinto","year":"1991","unstructured":"Pinto HA, Jacobs CJ (1991) Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 5:667","journal-title":"Hematol Oncol Clin North Am"},{"key":"CR4","first-page":"311","volume":"21","author":"GP Browman","year":"1994","unstructured":"Browman GP, Cronin L (1994) Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 21:311","journal-title":"Semin Oncol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1985.3.8.1105","volume":"3","author":"A Veronosei","year":"1985","unstructured":"Veronosei A, Zagonel V, Rirelli U, et al (1985) High dose versus low dose cisplatin in advanced head and neck squamous carcinoma. A randomized study. J Clin Oncol 3:1105","journal-title":"J Clin Oncol"},{"key":"CR6","volume-title":"Current perspectives and future directions","author":"M Al-Sarraf","year":"1990","unstructured":"Al-Sarraf M (1990) Management strategies in head and neck cancer: the role of carboplatin. In: Bunns PA Jr, Cannetta R, Ozols PF, Rozencweig M (eds) Current perspectives and future directions. Saunders, Philadelphia"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E, et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257","journal-title":"J Clin Oncol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"A Forastiere","year":"1992","unstructured":"Forastiere A, Metch B, Schuller D, et al (1992) Randomized comparison of cisplatin and 5-fluorouracil versus carboplatin + 5-fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:1245","journal-title":"J Clin Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/oxfordjournals.annonc.a058906","volume":"5","author":"M Clavel","year":"1994","unstructured":"Clavel M, Vermorken JB, Congetti F, et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin, and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 5:521","journal-title":"Ann Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/S0959-8049(99)81107-1","volume":"35","author":"V Adamo","year":"1999","unstructured":"Adamo V, Maisano R, Laudani A, et al (1999) Phase II study of paclitaxel and cisplatin in advanced and recurrent head and neck cancer. Eur J Cancer 35:S178","journal-title":"Eur J Cancer"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1023\/A:1008260817878","volume":"8","author":"L Licitra","year":"1997","unstructured":"Licitra L, Capri G, Fulfaro F, et al (1997) Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma: a phase II trial. Ann Oncol 8:1157","journal-title":"Ann Oncol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1008279503428","volume":"8","author":"G Foutzilas","year":"1997","unstructured":"Foutzilas G, Skarlos D, Athanassiades A, et al (1997) Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of the nasopharynx and other sites of the head and neck: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 8:451","journal-title":"Ann Oncol"},{"key":"CR13","first-page":"99","volume":"59","author":"TA Fong","year":"1999","unstructured":"Fong TA, Shawver LK, Sun L, Tang C, App H, Powell J, et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99?106","journal-title":"Cancer Res"},{"key":"CR14","first-page":"2798","volume":"8","author":"A Stopeck","year":"2002","unstructured":"Stopeck A, Sheldon, M, Vahedian M, Cropp G, Gosalia R, Hannah A (2002) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798?2805","journal-title":"Clin Cancer Res"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004?1014","journal-title":"N Engl J Med"},{"key":"CR16","first-page":"1843","volume":"2","author":"D Belotti","year":"1996","unstructured":"Belotti D, Vergani V, Drudis T, Borsotti P, et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843?1849","journal-title":"Clin Cancer Res"},{"key":"CR17","first-page":"647","volume":"41","author":"C Sweeney","year":"2000","unstructured":"Sweeney C, Sissions SE, Nakshatri H, Sledge GW, et al (2000) Overcoming resistance to the anti-angiogenic properties of docetaxel induced by endothelial cell stimulation (abstract 4110). Proc Am Assoc Cancer Res 41:647","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR18","first-page":"647","volume":"41","author":"K Hotchkiss","year":"2000","unstructured":"Hotchkiss K, Ashton A, Sparano J, Schwarz EL, et al (2000) Inhibition of endothelial cell function by docetaxel (abstract 4111). Proc Am Assoc Cancer Res 41:647","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"8","key":"CR19","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15?R24","journal-title":"J Clin Invest"},{"issue":"3","key":"CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbcuk SG, Eisenhauer EA, Wanders J, Kaplan RS, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205?216","journal-title":"J Natl Cancer Inst"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2002.20.6.1657","volume":"20","author":"BC Kuenen","year":"2002","unstructured":"Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657?1667","journal-title":"J Clin Oncol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0378-4347(93)80100-I","volume":"621","author":"TA Willey","year":"1993","unstructured":"Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621:231?238","journal-title":"J Chromatogr"},{"key":"CR23","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gilbaldi","year":"1982","unstructured":"Gilbaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York","edition":"2"},{"key":"CR24","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Williams & Wilkins, Baltimore","edition":"3"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2165\/00003088-199427040-00002","volume":"27","author":"DS Sonnichsen","year":"1994","unstructured":"Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256?269","journal-title":"Clin Pharmacokinet"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/oxfordjournals.annonc.a059287","volume":"6","author":"MT Huizing","year":"1995","unstructured":"Huizing MT, Vermorken JB, Rosing H, Bokkel WW, Huinink, Mandjes I, Pinedo HM, Beijnen JH (1995) Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 6:699?704","journal-title":"Ann Oncol"},{"key":"CR27","first-page":"53","volume":"71","author":"SM Longnecker","year":"1987","unstructured":"Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53?59","journal-title":"Cancer Treat Rep"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182?1186","journal-title":"N Engl J Med"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","volume":"333","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333:1757?1763","journal-title":"N Engl J Med"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1464-410X.1994.tb07122.x","volume":"74","author":"AJ Dickinson","year":"1994","unstructured":"Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris A (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74:762?766","journal-title":"Br J Urol"},{"key":"CR31","first-page":"3964","volume":"55","author":"Y Takahashi","year":"1995","unstructured":"Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964?3968","journal-title":"Cancer Res"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-9610(05)80079-0","volume":"168","author":"JK Williams","year":"1994","unstructured":"Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ (1994) Tumor angiogenesis as a prognostic factor in oral cavitary tumors. Am J Surg 168:373?380","journal-title":"Am J Surg"},{"key":"CR33","first-page":"95","volume":"6","author":"GF Cropp","year":"2000","unstructured":"Cropp GF, Hannah AL (2000) SU5416, a molecularly targeted novel anti-angiogenesis drug: clinical pharmacokinetics and safety review (abstract 262). 11th NCI-EORTC-AACR Symposium on new drugs in cancer therapy, 7?10 November. Clin Cancer Res 6 [Suppl 11]:95","journal-title":"Clin Cancer Res"},{"issue":"6","key":"CR34","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2002.20.6.1657","volume":"20","author":"BC Kuenen","year":"2002","unstructured":"Kuenen BC, Rosen L, Smit E, Parson ML, Ruijiter R, et al (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20(6):1657?1667","journal-title":"J Clin Oncol"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","volume":"21","author":"BC Kuenen","year":"2003","unstructured":"Kuenen BC, Levi M, Meijers JCM, van Hinsbergh VWM, Berkof J, Kakkar AK, Hoekman K, Pineodo HM (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21:2192?2198","journal-title":"J Clin Oncol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1242\/jcs.113.9.1525","volume":"113","author":"W Li","year":"2000","unstructured":"Li W, Keller G (2000) VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J Cell Sci 113:1525?1534","journal-title":"J Cell Sci"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1073\/pnas.96.15.8663","volume":"96","author":"K Abe","year":"1999","unstructured":"Abe K, Shoji M, Chen J, et al (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 96:8663?8668","journal-title":"Proc Natl Acad Sci U S A"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/excr.1997.3812","volume":"238","author":"DS Calnek","year":"1998","unstructured":"Calnek DS, Grinnell BW (1998) Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res 238:294?298","journal-title":"Exp Cell Res"},{"key":"CR39","first-page":"213","volume":"138","author":"TA Brock","year":"1991","unstructured":"Brock TA, Dvorak HF, Senger DR (1991) Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138:213?221","journal-title":"Am J Pathol"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"33057","DOI":"10.1074\/jbc.274.46.33057","volume":"274","author":"BQ Shen","year":"1999","unstructured":"Shen BQ, Lee DY, Zioncheck TF (1999) Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR\/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057?33063","journal-title":"J Biol Chem"},{"key":"CR41","first-page":"H1054","volume":"274","author":"JD Hood","year":"1998","unstructured":"Hood JD, Meininger CJ, Ziche M, et al (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054?H1058","journal-title":"Am J Physiol"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1242\/jcs.110.18.2293","volume":"110","author":"SJ Mandriota","year":"1997","unstructured":"Mandriota SJ, Pepper MS (1997) Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 110:2293?2302","journal-title":"J Cell Sci"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0006-291X(91)91276-I","volume":"181","author":"MS Pepper","year":"1991","unstructured":"Pepper MS, Ferrara N, Orci L, et al (1991) Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902?906","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0871-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-004-0871-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0871-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T18:02:59Z","timestamp":1624816979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-004-0871-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0871-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,6]]}}}